Emerald Advisers LLC Buys 49,540 Shares of Insmed Incorporated (NASDAQ:INSM)

Emerald Advisers LLC grew its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 7.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 689,807 shares of the biopharmaceutical company's stock after acquiring an additional 49,540 shares during the quarter. Insmed comprises about 2.0% of Emerald Advisers LLC's investment portfolio, making the stock its 5th largest holding. Emerald Advisers LLC owned about 0.46% of Insmed worth $50,356,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Nisa Investment Advisors LLC increased its position in shares of Insmed by 8.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company's stock valued at $119,000 after purchasing an additional 135 shares during the period. CWM LLC grew its holdings in Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 155 shares during the period. GAMMA Investing LLC lifted its holdings in Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 224 shares during the last quarter. First Horizon Advisors Inc. boosted its position in shares of Insmed by 83.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 287 shares in the last quarter. Finally, Atomi Financial Group Inc. boosted its position in shares of Insmed by 1.4% during the 3rd quarter. Atomi Financial Group Inc. now owns 23,248 shares of the biopharmaceutical company's stock valued at $1,697,000 after purchasing an additional 314 shares in the last quarter.

Insider Activity at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the business's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the transaction, the insider now directly owns 106,134 shares of the company's stock, valued at approximately $7,951,559.28. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares of the company's stock, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the transaction, the insider now directly owns 100,100 shares in the company, valued at $7,157,150. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 78,882 shares of company stock valued at $5,765,446 over the last ninety days. 4.60% of the stock is owned by insiders.

Insmed Price Performance

Insmed stock traded up $1.04 during trading hours on Friday, hitting $68.32. 1,617,227 shares of the stock were exchanged, compared to its average volume of 1,096,821. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The business's 50-day moving average is $73.03 and its two-hundred day moving average is $61.76. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The stock has a market capitalization of $11.74 billion, a P/E ratio of -12.31 and a beta of 1.12.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analysts' expectations of $93.36 million. Insmed's quarterly revenue was up 18.1% on a year-over-year basis. During the same period last year, the company earned ($1.10) earnings per share. Equities research analysts expect that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on INSM. Bank of America lifted their target price on Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, October 9th. HC Wainwright restated a "buy" rating and set a $90.00 price objective on shares of Insmed in a report on Friday. Morgan Stanley raised their target price on shares of Insmed from $60.00 to $85.00 and gave the stock an "overweight" rating in a report on Friday, July 12th. UBS Group boosted their price target on shares of Insmed from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday, August 9th. Finally, Stifel Nicolaus upped their price target on shares of Insmed from $74.00 to $88.00 and gave the company a "buy" rating in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $83.07.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.